Ainnova Tech, a Nevada-based health tech company headquartered in San Jose, Costa Rica, and Houston, Texas, has acquired OTCHealth for an undisclosed amount. This corporate acquisition sees Ainnova Tech absorbing OTCHealth, a company known for empowering healthcare with artificial intelligence, marking a significant step in Ainnova Tech's strategy for early disease detection.
Ainnova Tech specializes in leveraging artificial intelligence to create solutions for early disease detection. Its flagship platform, VisionAi, is designed to prevent blindness and detect the early onset of diabetes and cardiovascular risk by analyzing retinal images. The company has garnered multiple global awards and established partnerships with hospitals and a globally recognized medical device company, demonstrating its commitment to revolutionizing healthcare through advanced technology.
The acquisition of OTCHealth is strategically aimed at strengthening Ainnova Tech's overall capabilities in AI-driven healthcare solutions. By integrating OTCHealth's expertise in empowering healthcare with AI, Ainnova Tech expects to enhance its product portfolio, broaden its technological reach, and deepen its market penetration within the health tech sector. This move underscores Ainnova Tech’s dedication to developing streamlined, cost-efficient processes for medical specialists and improving patient outcomes.
This acquisition represents a clear consolidation of capabilities, positioning the combined entity to further innovate in AI-powered early disease detection. The unified organization is set to expand its efforts in bringing proactive, technology-driven solutions to a wider healthcare audience, ultimately furthering its mission of empowering healthcare with AI and making a substantial impact on global health.